Abbott
ABT

$105.24

5.62%

Market Cap: 183B

About: Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

Employees: 114,000

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 9 analysts

0

News positive %

of 42 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

5% more call options, than puts

Call options by funds: $1.21B | Put options by funds: $1.14B

2% more capital invested

Capital invested by funds: $143B [Q4 2023] → $146B (+$2.55B) [Q1 2024]

0% less funds holding

Funds holding: 2,803 [Q4 2023] → 2,797 (-6) [Q1 2024]

0% less repeat investments, than reductions

Existing positions increased: 1,107 | Existing positions reduced: 1,112

0.95% less ownership

Funds ownership: 75.09% [Q4 2023] → 74.13% (-0.95%) [Q1 2024]

3% less first-time investments, than exits

New positions opened: 179 | Existing positions closed: 185

16% less funds holding in top 10

Funds holding in top 10: 102 [Q4 2023] → 86 (-16) [Q1 2024]

See Fund Rankings

Research analyst outlook

9 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$119

13%

upside

Avg. target

$126

19%

upside

High target

$140

33%

upside

9 analyst ratings

9 positive

100%

0 neutral

0%

0 negative

0%

Evercore ISI Group Vijay Kumar	14%upside $120	Outperform Maintained	2 Jul 2024
RBC Capital Shagun Singh	19%upside $125	Outperform Reiterated	4 Jun 2024
Goldman Sachs David Roman	15%upside $121	Buy Initiated	30 May 2024
Citigroup Joanna Wiensch	13%upside $119	Buy Maintained	22 May 2024
Barclays Matt Miksic	33%upside $140	Overweight Maintained	22 Apr 2024

See Analyst Rankings

Financial journalist opinion

Based on 42 articles about ABT published over the past 30 days

Abbott must pay $495M in damages after girl develops dangerous disease from premature infant formula

A jury found that Abbott Laboratories' specialized formula for premature infants caused an Illinois girl to develop a dangerous bowel disease, ordering the healthcare company to pay $495 million in damages.

Abbott must pay $495M in damages after girl develops dangerous disease from premature infant formula

Abbott must pay $95 million in premature infant formula trial, jury finds

A jury on Friday found that Abbott Laboratories' specialized formula for premature infants caused an Illinois girl to develop a dangerous bowel disease, ordering the healthcare company to pay $95 million in compensatory damages.

Abbott must pay $95 million in premature infant formula trial, jury finds

Should You Pick Abbott Stock At $105 After A Solid Q2?

Abbott (NYSE: ABT) recently reported its Q2 results, with revenues and earnings exceeding our expectations. The company reported revenue of $10.4 billion and earnings of $1.14 on a per-share and adjusted basis, compared to our estimates of $10.3 billion and $1.10, respectively.

Should You Pick Abbott Stock At $105 After A Solid Q2?

The Motley Fool

Better Buy: Abbott Laboratories vs. Intuitive Surgical

Healthcare stocks are generally good bets, thanks to a rapidly growing population of older adults in the U.S. and other developed economies. Abbott Laboratories is growing sales at a high-single-digit annual percentage and offers a quarterly dividend.

Better Buy: Abbott Laboratories vs. Intuitive Surgical

The Motley Fool

3 High-Yielding Dividend Stocks That Can Help Bankroll Your Retirement Years

Abbott's diverse business and low beta value make it one of the safest dividend stocks you can own. Home Depot doesn't expect much growth this year, but that likely won't remain a long-term problem.

3 High-Yielding Dividend Stocks That Can Help Bankroll Your Retirement Years

Zacks Investment Research

Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know

Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know

The Motley Fool

10 Best Dividend Growth Stocks to Buy and Hold Forever

These blue-chip companies have demonstrated strong dividend growth rates ranging from 7.69% to 15.8% annually over the past five years. The list includes diverse sectors such as retail, healthcare, technology, and finance, offering potential for portfolio diversification.

10 Best Dividend Growth Stocks to Buy and Hold Forever

7 Safe Stocks to Buy for Volatility Insurance

The concept of safe stocks arguably couldn't be timelier. Recently, the technology sector encountered significant turmoil, with many experts questioning the sustained success of artificial intelligence and related innovations.

7 Safe Stocks to Buy for Volatility Insurance

Abbott Laboratories Posts Big Drop in COVID-19 Testing Revenue

Shares of Abbott Laboratories (ABT) declined in intraday trading Thursday as the healthcare products maker's sales of COVID-19 tests slumped with the pandemic ending.

Abbott Laboratories Posts Big Drop in COVID-19 Testing Revenue

Nasdaq Down Over 100 Points; Abbott Laboratories Earnings Beat Views

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling more than 100 points on Thursday.

Nasdaq Down Over 100 Points; Abbott Laboratories Earnings Beat Views

See News Rankings